Ikena Oncology, Inc. (IKNA) announced the results of its July 15, 2025 annual stockholders meeting, where all proposals were approved, including the merger with Inmagene Biopharmaceuticals.
After the merger closes, Ikena plans to change its name to ImageneBio, Inc. and trade on The Nasdaq Capital Market under the ticker symbol “IMA.”
Shareholders also approved a reverse stock split, empowering the board to select a ratio between 1-for-5 and 1-for-15. Ikena will implement a 1-for-12 reverse stock split of its common stock, expected to take effect around the end of July before the merger closes.
